[Gujarat, India — 2026-03-10] — Premier Medical Corporation is pleased to announce the launch of the First Response® Malaria Ag. P.f. (HRP2)/P.f. (pLDH)/P.v. (pLDH) Test, a rapid, qualitative in vitro diagnostic solution designed to support the detection and differentiation of Plasmodium falciparum and Plasmodium vivax malaria infections in both laboratory and point-of-care settings.

Developed for use by trained healthcare professionals, this innovative test enables reliable detection of P. falciparum Histidine-Rich Protein 2 (HRP2), P. falciparum parasite Lactate Dehydrogenase (pLDH), and P. vivax parasite Lactate Dehydrogenase (pLDH) antigens. Its straightforward, easy-to-interpret format enhances usability while maintaining exceptional diagnostic performance.

With high sensitivity and specificity, the First Response® Malaria Ag. P.f. (HRP2)/P.f. (pLDH)/P.v. (pLDH) Test provides the dependable performance healthcare professionals need to support timely diagnosis and treatment decisions. Delivering rapid results within 20–30 minutes, it enables efficient malaria screening in high-throughput environments and resource-limited settings.

Key Product Features

• Qualitative detection of Plasmodium falciparum and Plasmodium vivax malaria infections
• Simultaneous detection of P.f. (HRP2), P.f. (pLDH), and P.v. (pLDH) antigens
• Supports differentiation between P. falciparum and P. vivax infections
• Rapid results within 20–30 minutes
• Suitable for laboratory and point-of-care testing
• Whole blood specimen
• Stable storage at 1°C – 40°C
• Simple, user-friendly lateral flow test format

Premier Medical Corporation continues to advance high-quality diagnostic technologies that strengthen early detection and improve health outcomes globally.

For more information about the First Response® Malaria Ag. P.f. (HRP2)/P.f. (pLDH)/P.v. (pLDH) Test, please contact our customer support team or visit our product pages.